May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Risk Should Dictate the Aggressiveness of Prostate Cancer Treatment
February 5th 2016Matthew Cooperberg, MD genitourinary cancer specialist, University of California San Francisco (UCSF), discusses the varying management techniques for both low- and high-risk prostate cancers, including radiation therapy, surgery, hormonal therapy, and active surveillance.
Read More
Dr. Daniel Hamstra on the Benefits of Shorter Radiation Therapy Sessions for Prostate Cancer
February 4th 2016​Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.
Watch
Dr. Matthew Cooperberg on New Aspects of the Treatment Paradigm for Prostate Cancer
February 3rd 2016Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the appropriateness of a more aggressive approach to men with high-risk prostate cancer. Cooperberg says currently, men will normally respond to surgery followed by adjuvant radiotherapy, as well as systemic therapy.
Watch
Radium-223 Retreatment Deemed Safe in Bone-Metastatic Prostate Cancer
February 3rd 2016Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC), according to a recent prospective, open-label phase I/II trial.
Read More
Dr. Tomasz M. Beer on BRCA Gene Defects in Advanced Prostate Cancer
January 16th 2016Beer says that while BRCA is normally associated with breast cancer, the gene is found in up to 20% of advanced prostate cancers. He says of this 20% patient population, roughly half inherit the BRCA gene and the other half acquire it.
Watch
Dr. Daniel Hamstra on the Noninferiority of Shorter Radiotherapy Regimens in Prostate Cancer
January 12th 2016Hamstra says that shorter regimens of radiotherapy for men whose prostates remained in tact post-surgery proved to be noninferior when compared to longer regimens. He adds that these shorter regimens are more convenient for patients, as well as more cost effective.
Watch
Hypofractionated Radiotherapy Noninferior to Standard Radiation Therapy
January 9th 2016Hypofractionated radiotherapy and standard radiation therapy demonstrated similar toxicities and neither prevented PSA increases or disease recurrences for men with intermediate-risk prostate cancer better than the other, according to data from the phase III randomized CHHiP trial reported at the 2016 GU Cancers Symposium.
Read More
Atezolizumab Could Change Standard of Care in Metastatic Urothelial Cancers
January 9th 2016Second-line treatment with atezolizumab (MPDL3280A) resulted in a median overall survival (OS) of 11.4 months in patients with locally advanced or metastatic urothelial carcinoma (mUC) and who showcased high PD-L1 levels.
Read More
Docetaxel Becomes the First Treatment Choice Post-Abiraterone in 50% of Patients with mCRPC
January 9th 2016A post hoc analysis of the phase III COU-AA-302 clinical trial suggests docetaxel can produce antitumor activity as the first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naive, metastatic castration-resistant prostate cancer.
Read More
DNA Repair Defects Vital to PARP Inhibitor's Strength in Prostate Cancer
January 9th 2016A current estimation shows that roughly 25% of metastatic castration-resistant prostate cancers (mCRPC) contain alterations in DNA repair genes. These would normally code for proteins to correct errors arising when cells duplicate their DNA before cell division.
Read More
Dr. Oliver Sartor on the Future of Identifying Phenotypic and Genomic Heterogeneity in mCRPC
January 8th 2016Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.
Watch
Liquid Biopsy Further Expands Prostate Cancer Treatment Armamentarium
January 5th 2016Resistance to androgen receptor therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) has historically posed a challenge to clinicians. Now, a new blood test that analyzes circulating tumor cells (CTCs) could help overcoming these hurdles.
Read More
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Read More
Advanced Prostate Cancer Clinics Begin to Mesh With Practices
December 18th 2015Urologists face a challenge in delineating the optimal sequence of treatment more and more as the goal for treating prostate cancer moves toward greater use of targeted therapies. While these treatment eradicate disease, urologists must minimize the risk of adverse events.
Read More
Healthy Living May Reduce Risk of Severe Prostate Cancer By Over Half
December 4th 2015Living a healthier lifestyle could be a robust preventative measure against metastatic prostate cancer. One new study suggests that leading a healthy lifestyle could reduce a man's chances of developing the cancer by up to 68%.
Read More
Studies Suggest Radical Prostatectomy May Be Optimal in Men With High-Risk Prostate Cancer
December 3rd 2015Recent studies suggest that RP may be a better initial treatment given many of these patients require multimodal therapy to manage their disease. The question about radiation versus surgery lies in the details, with treatment tailored to each patient.
Read More
The Potential of Radium-223 as a Treatment in mCRPC
November 13th 2015From its approval in May 2013 to recently being considered as a combination treatment with other drugs, radium-223 dichloride shows great potential in positively impacting treatment for mCRPC, according to Dr. Michael Morris.
Read More
Dr. Aaron Spitz on the Role of Telemedicine in Urology
November 12th 2015Aaron Spitz, MD, talks about the emerging uses of telemedicine in urology. Telemedicine allows medical professionals to remotely diagnose and sometimes even treat patients through a variety of technology, including smartphones and tablet devices.
Watch
Deliver Androgen Blockade to Achieve Castrate Levels in Prostate Cancer Cells
November 11th 2015"We should be doing this, because we understand the disease, we see these patients, and we're not just surgeons, Dr. Adam Kibel said. "We were giving them medications to control their BPH before we diagnosed them with cancer."
Read More